Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Rhea-AI Summary

Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company focused on retinal diseases, will present virtually at the Evercore ISI 5^th Annual HealthCONx Conference on November 29, 2022, at 9:10 am PT. A live webcast will be available on Kodiak's website and will remain accessible for replay afterward. The company specializes in developing transformative therapeutics, with its lead candidate, tarcocimab tedromer, targeting retinal vascular diseases like wet age-related macular degeneration. Kodiak leverages its ABC Platform™ to innovate treatments for significant causes of blindness.

PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present virtually at the Evercore ISI 5^th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).

A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform^™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.

Kodiak^®, Kodiak Sciences^®, ABC^™, ABC Platform^™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-evercore-isi-5th-annual-healthconx-conference-301680614.html

SOURCE Kodiak Sciences Inc.

FAQ

When will Kodiak Sciences present at the Evercore ISI HealthCONx Conference?

Kodiak Sciences will present virtually on November 29, 2022, at 9:10 am Pacific Time.

Where can I watch the Kodiak Sciences conference presentation?

The presentation can be viewed live on Kodiak's website under the 'Events and Presentations' section.

What is the focus of Kodiak Sciences Inc.?

Kodiak Sciences specializes in developing therapeutics for high prevalence retinal diseases.

What is Kodiak's lead product candidate?

Kodiak's lead product candidate is tarcocimab tedromer, aimed at treating retinal vascular diseases.

What is the ABC Platform™ used by Kodiak Sciences?

The ABC Platform™ combines antibody-based and chemistry-based therapies for innovative retinal medicine development.